Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s ...

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...

Eli Lilly's tirzepatide leads to 50% more weight loss compared to Novo Nordisk's semaglutide in 72-week study.

A study of two blockbuster weight-loss drugs showed that users of Eli Lilly’s Zepbound lost just over 2 inches more off their ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

In today’s Health Alert, two popular weight loss drugs went head-to-head in a clinical trial – and one came out on top.

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...

A trial was conducted comparing weight loss medications Zepbound and Wegovy. Results from the trial found that participants ...

Eli Lilly ( NYSE: LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's ( ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...